News | January 31, 2008

Heart Disease Ranked Most Expensive of Top 10 Health Conditions

February 4, 2008 - Heart conditions cost $76 billion to treat in 2005, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

The nation’s 10 most expensive medical conditions costs totaled an estimated $500 billion to treat in 2005, said the survey. This includes money paid for visits to doctor's offices, clinics and emergency departments, hospital stays, home health care and prescription medicines.

Estimated spending for the 10 most expensive conditions:
1. Heart conditions $76 billion
2. Trauma disorders $72 billion
3. Cancer $70 billion
4. Mental disorders, including depression $56.0 billion
5. Asthma and chronic obstructive pulmonary disease $54 billion
6. High blood pressure $42 billion
7. Type 2 diabetes $34 billion
8. Osteoarthritis and other joint diseases $34 billion
9. Back problems $32 billion
10.Normal childbirth $32 billion

AHRQ, which is part of the U.S. Department of Health and Human Services, works to enhance the quality, safety, efficiency and effectiveness of health care in the United States. The data in this AHRQ News and Numbers summary are taken from the Medical Expenditure Panel Survey, a detailed source of information on the health services used by Americans, the frequency with which they are used, the cost of those services and how they are paid.

For more information: www.ahrq.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now